Neurological Sciences

, Volume 29, Supplement 2, pp 271–273

Intracerebral hemorrhage: medical treatment

Annual Meeting of SIN/SNO Lombardia


Intracerebral hemorrhage (ICH) accounts for between 10% to 30% of first-ever strokes; outcomes are significantly worse than with ischemic stroke with a 30-day mortality rate up to 50%, furthermore, half of the deaths occur in the acute phase. Intracerebral hemorrhage (ICH) is classified as primary or secondary according to the underlying etiology. Primary ICH (about 80%) comes from the spontaneous rupture of small vessels more often in relation to long-standing or uncontrolled arterial hypertension and is generally located in the basal ganglia and internal capsula. Secondary ICH (about 20%) is often associated with vascular abnormalities, tumors, and anticoagulant therapy or coagulation disorders, more frequently located in cerebral lobes or subtentorial (cerebellum or pons). Rapid recognition and diagnosis of ICH as well as identification of early prognostic indicators are essential for planning the level of care and avoiding acute rapid progression during the first hours. Hematoma size has been identified as one of the most important predictors of 30-day mortality and its expansion is highly predictive of neurological deterioration [1]. Blood pressure management remains, although controversial, the first-line medical approach along with possible new and effective treatments coming from the numerous between pilot and larger randomized medical trials for ICH completed in the past decade.


Intracerebral hemorrhage Medical management 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Broderick J, Brott TG, Duldner JE et al (1993) Volume of intracerebral hemorrhage: a powerful and easy-to-use predictor of 30-day mortality. Stroke 24:987–993PubMedGoogle Scholar
  2. 2.
    Neeraj SN, Nyquisit PA, Carhuapoma JR (2007) Advances in the management of spontaneous intracerebral hemorrhage. Crit Care Clin 607–617Google Scholar
  3. 3.
    Broderick J, Connolly S, Feldmann E et al (2007) Guidelines for the management of spontaneous intracerebral hemorrhage in adults. 2007 Update. Stroke 38:2001–2023PubMedCrossRefGoogle Scholar
  4. 4.
    Qureshi AI (2007) Antihypertensive treatment of acute cerebral hemorrhage (ATACH). Neurocrit Care 06:56–66CrossRefGoogle Scholar
  5. 5.
    Mayer SA, Brun NC, Broderick J et al (2005) Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 36:74–79PubMedCrossRefGoogle Scholar
  6. 6.
    Mayer S, Brun NC, Begtrup K et al (2005) Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352:777–785PubMedCrossRefGoogle Scholar
  7. 7.
    Mayer S (2007) Recombinant activated factor VII for acute intracerebral hemorrhage. Stroke 38:763–767PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2008

Authors and Affiliations

  1. 1.Istituto Auxologico Italiano, IRCCSU. O. Cardiologia Ospedale San LucaMilanoItaly

Personalised recommendations